Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 108, Issue 4, Pages 365-370Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s12185-018-2519-y
Keywords
BCR-ABL; Chronic myeloid leukemia; Leukemia stem cells; Tyrosine kinase inhibitors
Categories
Funding
- National Institute of Biomedical Innovation
- Ministry of Education, Culture, Sports, Science and Technology on Scientific Research, Japan
Ask authors/readers for more resources
Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors (TKI) targeted against BCR-ABL. We previously reported the investigation of residual CML diseases during TKI treatment using FACS-sorting and quantitative RT-PCR of BCR-ABL among each population; total mononuclear cells, hematopoietic stem cells, and myeloid progenitors. The observations also implied that the second-generation of ABL-tyrosine kinase inhibitors (2nd TKIs), dasatinib or nilotinib therapy can be more promising approach for efficient reduction of the CML stem cells. Moreover, we need to develop the evaluation method of the residual CML diseases to establish rational therapy-cessation strategies in CML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available